1. Home
  2. Companies
  3. AVR
  4. Material Events

Anteris Technologies Global (ASX:AVR) — Material Events

ASX:AVR · 23 articles in the last 12 months · 100% assessed

Click a band to jump to that tier

Major 1 article Significant 20 articles Notable 2 articles Not Assessed 0 articles
Major ≥90 Significant 75–89 Notable 50–74 Routine <50 Not assessed
Significant Score 75–89
20
Anteris Secures FDA Nod, Kicks Off PARADIGM Trial Across US and EuropeMedium
Anteris Advances PARADIGM Trial with FDA Approval, Reports Q3 2025 Financials
13 Nov 2025 ·Quarterly Financial Results ·85
Anteris Advances DurAVR Trial Amid $65M Loss and $25M Capital RaiseHigh
Anteris reports Q3 2025 loss, advances DurAVR THV pivotal trial, raises $25M in private placement
13 Nov 2025 ·Form 10-Q Quarterly Report ·85
Anteris Launches Global Trial for Innovative DurAVR Heart ValveMedium
Anteris Secures First European Clearance to Launch Global DurAVR Heart Valve Trial
16 Oct 2025 ·Regulatory Announcement ·85
Anteris Secures $290M Boost with Medtronic Backing for Heart Valve TrialsHigh
Anteris Technologies announces $200M public offering and $90M strategic investment from Medtronic
21 Jan 2026 ·Capital Raising ·85
Anteris Technologies Raises $230M to Propel DurAVR Heart Valve Trials and ManufacturingHigh
Anteris Technologies launches $230M equity offering alongside $84M private placement to advance DurAVR heart valve clinical trials and manufacturing
22 Jan 2026 ·Prospectus Supplement ·85
Anteris Secures $90M Medtronic Backing to Propel DurAVR Heart Valve TrialHigh
Anteris secures $90M Medtronic investment in $320M raise to advance DurAVR TAVR trial and commercialization
23 Jan 2026 ·Capital Raising ·85
Anteris Launches Global Trial for Innovative DurAVR Heart ValveMedium
Anteris Technologies initiates global pivotal PARADIGM Trial for DurAVR Heart Valve
28 Oct 2025 ·Clinical Trial Announcement ·85
Anteris Reports $94.2M Loss, Advances DurAVR THV Trial, Raises $320M in 2026High
Anteris reports $94.2M loss in 2025, advances DurAVR THV pivotal trial, raises $320M in early 2026 financings
27 Feb 2026 ·Annual Report (Form 10-K) ·85
Anteris Launches Global Trial After FDA Nod for DurAVR Heart ValveMedium
Anteris Secures FDA Approval to Launch Global PARADIGM Trial for DurAVR Heart Valve
3 Nov 2025 ·Regulatory Approval Announcement ·85
Anteris Secures $320M to Propel DurAVR Heart Valve Trials and ExpansionHigh
Anteris closes $320M equity raise including Medtronic private placement to fund heart valve trials and growth
23 Jan 2026 ·Capital Raising ·85
Anteris Technologies Secures A$38.5M to Propel DurAVR® TAVR Trial and Commercial LaunchMedium
Anteris Technologies raises A$38.5M to advance DurAVR® TAVR commercialization and pivotal PARADIGM trial
28 Oct 2025 ·Capital Raising ·85
Anteris Technologies Accelerates DurAVR® Valve Progress with $25M Raise and Trial ApprovalsMedium
Anteris Technologies Advances DurAVR® Valve Development with Regulatory Approvals and $25M Capital Raise
4 Dec 2025 ·Annual Meeting Presentation ·85
Anteris Technologies Launches $250M ATM Stock Offering to Fund DurAVR DevelopmentMedium
Anteris Technologies launches $250M at-the-market stock offering to fund heart valve development
25 May 2026 ·Capital Raising ·80
Anteris Secures Medicare Reimbursement to Boost US PARADIGM Trial ActivationMedium
Anteris Technologies Secures U.S. Medicare Reimbursement for PARADIGM Trial
28 Apr 2026 ·Regulatory Update ·80
Anteris Advances DurAVR Trial with 130 Patients Treated and New Board AppointmentsMedium
Anteris reports Q2 2025 results, advances DurAVR clinical trial preparations and board appointments
12 Aug 2025 ·Quarterly Financial Results ·80
Anteris Raises $320M, Advances DurAVR Trial with US EnrollmentMedium
Anteris raises $320M, advances PARADIGM Trial with US enrollment and reports Q1 2026 cash outflows of $28.7M
13 May 2026 ·Quarterly Financial Results ·80
Anteris Enrolls First US Patients in Pivotal DurAVR Heart Valve TrialMedium
Anteris Technologies Treats First U.S. Patients in Global PARADIGM Heart Valve Trial
6 May 2026 ·Clinical Trial Update ·80
Anteris Secures ASX Waiver and Navigates PARADIGM Trial DelayMedium
Anteris Technologies approves ASX waiver and updates PARADIGM trial delay to Q4 2025
30 Sept 2025 ·Results of Special Meeting and Clinical Trial Update ·75
Anteris Technologies Posts $42.7M Loss, Gears Up for Pivotal DurAVR TrialHigh
Anteris Technologies reports $42.7M loss in H1 2025, advances DurAVR THV trial preparations, IPO proceeds support R&D
12 Aug 2025 ·Form 10-Q Quarterly Report ·75
Anteris Registers 9.1M Shares for Resale, Fuels DurAVR Trial MomentumMedium
Anteris Technologies files SEC Form S-1 to register shares for resale following private placement, advancing DurAVR heart valve development and clinical trials
27 Nov 2025 ·SEC Form S-1 Registration Statement ·75
Not Assessed Low Score, or missing data
0

No articles in this tier for the last 12 months.